The MORDOR I trial (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) showed that twice-yearly azithromycin distributions reduced childhood mortality by 14% in communities in Niger, Malawi, and Tanzania (and unpublished data). The greatest observed benefit was seen in Niger,…